Speaker Profile
VP, Director PharmaDx Program, ARUP Laboratories Adjunct Associate Professor of Pathology, University of Utah School of Medicine
Biography
Dr. Heichman’s role involves both developing and managing scientific and business collaborations, with a special emphasis on those involving the pharmaceutical industry. Dr. Heichman led the team that developed and received FDA approval for ARUP’s two companion diagnostic tests in support of Novartis’ Gleevec rare diseases program. She has >25 years of scientific experience in both corporate and academic institutions. Prior to ARUP, she spent several years at Myriad Genetics where she was the VP of Proteomic Research and three years at the Huntsman Cancer Institute as the Director of Cancer Systems Biology and Resources. Dr. Heichman holds an AB in genetics from UC Berkeley, a PhD in Biological Chemistry from UCLA School of Medicine and conducted postdoctoral training from the Fred Hutchinson Cancer Research Center.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Firms that develop companion diagnostics face numerous challenges. Among them are attracting a pharma partner, FDA procedures and regulations, reimbursement and engaging labs to run their tests. This panel will discuss those challenges as well as the incentives for developing and selling companion diagnostics.
